Compare RPID & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | LONA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 32.7M |
| IPO Year | 2021 | 2020 |
| Metric | RPID | LONA |
|---|---|---|
| Price | $0.74 | $3.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.00 | ★ $16.67 |
| AVG Volume (30 Days) | ★ 151.4K | 56.3K |
| Earning Date | 11-27-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,587,000.00 | N/A |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $17.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $0.58 | $2.21 |
| 52 Week High | $4.94 | $14.21 |
| Indicator | RPID | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 26.74 |
| Support Level | $0.58 | $2.21 |
| Resistance Level | $2.18 | $9.78 |
| Average True Range (ATR) | 0.07 | 0.44 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 66.24 | 3.27 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.